Capricor Therapeutics CAPR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's accrued expenses?
- Capricor Therapeutics (CAPR) reported accrued expenses of $10.53M in Q1 2026.
- How has Capricor Therapeutics's accrued expenses changed year-over-year?
- Capricor Therapeutics's accrued expenses increased by 148.2% year-over-year, from $4.24M to $10.53M.
- What is the long-term trend for Capricor Therapeutics's accrued expenses?
- Over 3 years (2022 to 2025), Capricor Therapeutics's accrued expenses has grown at a 458.6% compound annual growth rate (CAGR), from $89.23K to $15.56M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.